James McLennan
Family Medicine · Casper, WYNPI 1487004511
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 589 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,326, 2.6 times the $1,261 reported in 2020. Among family medicine clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 589 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$1K
- Novo Nordisk$1K
- Bayer$995
- Esperion Therapeutics, Inc.$914
- Lilly USA, LLC$881
- plus $5K from 30 others
What the payments were for
- Food & beverage$13,31299%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 127 | $2,974 |
| AbbVie | 68 | $1,431 |
| Novo Nordisk | 55 | $1,281 |
| Bayer | 39 | $995 |
| Esperion Therapeutics, Inc. | 46 | $914 |
| Lilly USA, LLC | 33 | $881 |
| Corcept Therapeutics | 33 | $855 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $750 |
| Amgen(2 entities) | 30 | $610 |
| Boehringer Ingelheim | 18 | $385 |
| Exact Sciences | 14 | $261 |
| Novartis | 10 | $230 |
| Insulet Corporation | 9 | $209 |
| Xeris Pharmaceuticals, Inc. | 1 | $198 |
| Pfizer | 7 | $163 |
| Kowa Pharmaceuticals America, Inc. | 6 | $137 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $112 |
| Alnylam Pharmaceuticals Inc. | 4 | $96 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| Merck | 4 | $69 |
| Biohaven Pharmaceuticals, Inc. | 4 | $66 |
| Recordati_rare_diseases_inc. | 3 | $65 |
| GSK | 4 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Tactile Systems Technology Inc | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Abbott | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Indivior Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,411 in reported general payments places this provider in the 95th percentile of 237 family medicine providers in Wyoming.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 14 | $279,346 |
| OzempicSemaglutide | 57 | $85,371 |
| JardianceEmpagliflozin | 53 | $83,261 |
| TradjentaLinagliptin | 21 | $27,373 |
| KerendiaFinerenone | 21 | $20,373 |
| FarxigaDapagliflozin Propanediol | 13 | $17,251 |
| EliquisApixaban | 13 | $16,582 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,254 |
| Telmisartan | 103 | $3,879 |
| Rosuvastatin Calcium | 166 | $3,510 |
| SynthroidLevothyroxine Sodium | 27 | $2,598 |
| Ezetimibe | 58 | $1,784 |
| Buprenorphine Hcl | 24 | $1,593 |
| Metformin Hcl ErMetformin Hcl | 92 | $1,572 |
| Atorvastatin Calcium | 90 | $1,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $855 | $279,34614 claims |
| Boehringer IngelheimJardiance, Tradjenta | $385 | $110,63474 claims |
| Novo NordiskOzempic | $1,281 | $85,37157 claims |
| BayerKerendia | $995 | $20,37321 claims |
| AstraZenecaFarxiga | $2,974 | $17,25113 claims |
| PfizerEliquis | $163 | $16,58213 claims |
| GSKBreo Ellipta | $65 | $8,25422 claims |
| AbbVieSynthroid | $1,431 | $2,59827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Casper
- Joseph SchoeberCasper$176K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Louis RoussalisCasper$5K
- Joseph MickelsonCasper$5K
- Jonathan BinderCasper$4K
- Sherrill FoxCasper$4K
- Taylor PedersenCasper$4K
- Tiffany SpauldingCasper$2K
- Brehan NewellCasper$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.